Find what matters to you

Patient advocacy is vital for advancement in managing disease. We met with Chandrabali Ghose-Paul, Chief Scientific Officer, Emily’s Entourage and Gary Joyner, Chairman Emeritus, Board of Directors, Primary Ciliary Dyskinesia (PCD) Foundation to discuss the role of patient advocacy groups

From the continuous development of clinical trial and data platforms to the ever-increasing complexity of therapeutic landscapes, understanding the best approach towards conducting feasibility for a clinical trial can prove daunting. Through our expertise in the most innovative feasibility tools and data platforms, we combine these data sources with our operational experience to put forth the most comprehensive, data-driven approaches to starting clinical studies off on the right foot.

Personalized medicine has a complexity problem. In Parkinson’s, this complexity problem is far-reaching and access-limiting. Dr. Schmidt presents his insight from bench research, clinical trials, and care workflow optimization to explore how optimized

Information discussing the transition to DCTs and their challenges, alongside the integration of data collection technology and best practices for sharing DCT data.

While a 505(b)(2) NDA can potentially get a drug to market faster than a 505(b)(1) NDA, the choice of a bridging strategy to the listed drug is important and involves consideration of multiple factors.

It’s in the collective best interest of research sponsors, participants, and sites to get clinical trials up and running faster and with the right safety surveillance mechanisms in place. But all too often, challenges and complexities stand in the way of efficient trial activation, enrollment, and post-activation monitoring.

The development of a gene therapy (GT) product has many considerations that differ from those of a traditional biologic or new chemical entity (NCE) program.